Triple-Negative Breast Cancer Clinical Trials in Los Angeles, California
17 recruitingLos Angeles, California
Showing 1–17 of 17 trials
Recruiting
Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled350 locationsNCT05633654
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Triple-Negative Breast CancerEsophageal CancerPancreatic Cancer+11 more
Eli Lilly and Company420 enrolled33 locationsNCT06465069
Recruiting
Phase 1
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
Triple-Negative Breast Cancer
University of Southern California20 enrolled1 locationNCT05989828
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 1
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Triple-Negative Breast CancerColorectal, CancerNon-small Cell Lung Cancer+2 more
Novartis Pharmaceuticals162 enrolled31 locationsNCT06562192
Recruiting
Phase 2
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Breast CancerTNBC - Triple-Negative Breast Cancer
Stephen Shiao35 enrolled1 locationNCT05491226
Recruiting
Phase 1
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 2
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
TNBC - Triple-Negative Breast CancerEarly Stage Triple-Negative Breast CarcinomaTNBC
Cedars-Sinai Medical Center34 enrolled4 locationsNCT07017673
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1Phase 2
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Triple-Negative Breast Cancer
Gilead Sciences100 enrolled16 locationsNCT06926920
Recruiting
Phase 2
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Triple-Negative Breast Cancer
Providence Health & Services12 enrolled4 locationsNCT06353997
Recruiting
Phase 1
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Triple-Negative Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Cancer+11 more
OncoNano Medicine, Inc.168 enrolled16 locationsNCT06022029
Recruiting
Phase 1Phase 2
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Triple-Negative Breast CancerAdvanced Solid TumorHead and Neck Squamous Cell Carcinoma+7 more
Volastra Therapeutics, Inc.200 enrolled14 locationsNCT05902988
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Triple-Negative Breast CancerColorectal, CancerLung Cancer+14 more
A2 Biotherapeutics Inc.240 enrolled10 locationsNCT06682793
Recruiting
Phase 2
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Breast CancerHER2-negative Breast CancerTNBC - Triple-Negative Breast Cancer
Processa Pharmaceuticals90 enrolled13 locationsNCT06568692